Immunohistochemical expression of markers KI-67, NeuN, synaptophysin, p53 and HER2 in medulloblastoma and its correlation with clinicopathological parameters

Arquivos de Neuro-Psiquiatria

Volumn 66, Issue 2 B, 2008, Pages 385-390

  Meurer, Rosalva Thereza ^a,b,d   Martins, Daniele Tondolo ^b   Hilbig, Arlete ^b,c   Ribeiro, Marlise De Castro ^b   Roehe, Adriana Vial ^b,c   Barbosa Coutinho, Ligia Maria ^b   Fernandes, Marilda Da Cruz ^b,c,d  

^a Fundação Faculdade Federal de Ciências Médicas de Porto Alegre   (Brazil)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d UFRGS ^*  (Brazil)

Author keywords

HER2; Immunohistochemistry; Ki 67; Medulloblastoma; NeuN; p53; Survival analysis; Synaptophysin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; NEURON SPECIFIC NUCLEAR PROTEIN; PROTEIN P53; SYNAPTOPHYSIN; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MEDULLOBLASTOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; SEX DIFFERENCE;

EID: 47749113717     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2008000300020     Document Type: Article

References (25)

1. Ellison DW, Clifford SC., Gajjar A, Gilbertson J R. What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediat Neurol 2003;7:53-66.
2. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004;22:984-993.
3. Chang C H, Housepian EM, Herbert C JR. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 1969;93:1351-1359.
4. Gilbertson JR. Medulloblastoma: signalling a change in treatment. Lancet Oncol 2004;5:209-218.
5. Rutkauskiené G, Labanauskas L, Jarusevicius L. The results of the treatment of childhood medulloblastoma with radiotherapy at Kaunas University of Medicine Hospital in 1994- 2000. Medicina (Kaunas) 2006;42(1).
6. Ellison D. Classifying the meduloblastoma;insights from morphology and molecular genetics. Neuropathol App Neurobiol 2002;28:257-282.
7. Grotzer MA, Geoerger B, Janss AJ, et al. Prognostic significance of Ki-67(MIB-1) proliferation index in childhood primitive neuroectodermal tumors of the central nervous system. Med Pediat Oncol 2001;36:268-273.
8. Ito S, Hoshino T, Prados MD, Edwards MSB. Cell kinetics of medulloblastoma. Cancer 1992;70:671-678.
9. Lantos PL, Louis DN, Rosenblum MK, Kleihues P. Tumours of the nervous system. In Graham DI, Lantos PL (eds). Greenfield's neuropathology. London: Arnold 2002;2:882-894.
10. Preusser M, Laggner U, Haberler C, et al. Comparative analysis of NeuN immunoreactivity in primary brain tumours: conclusions for rational use in diagnostic histopathology. Histopathology 2006;48:438-444.
11. Gilbertson RJ, Pearson ADJ., Perry RH, et al.. Prognostic significant of the c-erbB2 oncogene product in childhood medulloblastoma. Br J Cancer 1995;71:473-477.
12. Herms JW, Behnke J, Bergmann M, et al. Potential prognostic value of C-erbB-2 Expression in Medulloblastomas in very young children. J Pediat Hematol/Oncol 1997;19:510-515.
13. Gilbertson RJ. ERBB2 in pediatric Cancer: innocent until proven guilty. The Oncologist 2005;7:508-517.
14. Jaros E, Lunec J, Perry RH, et al. P53 protein overexpression identifies a group of central primitive neuroectodermal tumours with poor prognosis. Br J Cancer 1993;68:801-807.
15. Wooburn RT, Azzarelli B, Montebello J.F, Goss IE. Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors. J Neuro-Oncol 2001;52:57-62.
16. Brandes AA, Paris MK. Review of the prognostic factors in medulloblastoma of children and adults. Crit Rev Oncol/Hematol 2004;50:121-128.
17. Ray A, Ho M, Ma J, et al. A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res 2004;10:7613-7620.
18. Weil MD, Lamborn K, Edwards MS, Wara WM. Influence of a child's sex on medulloblastoma outcome. JAMA 1998;13:279:1474-1476.
19. Urberuaga A, Navajas A, Burgos J, Pijoán JI. A review of clinical and histological features of Spanish paediatric medulloblastomas during the last 21 years. Childs Nerv Syst 2005;22:466-474.
20. Ferrari AF, Araújo MBM, Aguiar PH, Plese JPP. Medulloblastoma: evaluation of proliferative index by monoclonal antibody Mib-1, its prognostic correlation and therapeutic implications. Arq Neuropsiquiatr 2003;61:3A.
21. Kayaselçuk F, Zorludemir S, Gümürdülü D, et al. PCNA and Ki-67 in central nervous system tumors: correlation with the histological type and grade. J Neuro-Oncol 2002;57:115-121.
22. Miralbell R, Tolnay M, Bieri S, et al. Pediatric medulloblastoma: prognostic value of p53, bcl-2, Mib-1, and microvessel density. J Neuro-Oncol 1999;45:103-110.
23. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci 2000;910:121-137; discussion 137-139.
24. Gilbertson RJ, Wickramasinghe C, Herman R, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001;85:705-712.
25. Nam DH, Wang KC, Kim YM, et al. The effect of isochromosome 17q presence, proliferative and apoptotic indices, expression of C-erbB-2, bcl-2 and p53 proteins on the prognosis of medulloblastoma. J Korean Med Sci 2000;15:452-456.